[More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors].
Jian-Ming
JM
Xu
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D005770:Gastrointestinal Neoplasms / Q000145:classification / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D018358:Neuroendocrine Tumors / Q000145:classification / Q000453:epidemiology / Q000628:therapy*; D015282:Octreotide / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000145:classification / Q000453:epidemiology / Q000628:therapy*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077210:Sunitinib
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007211:Indoles; D010456:Peptides, Cyclic; D011758:Pyrroles; C060347:lanreotide; D000068258:Bevacizumab; D013004:Somatostatin; C401859:temsirolimus; D015282:Octreotide; D000077210:Sunitinib; D020123:Sirolimus